Phenobarbital promotes liver growth in c-myc/TGF-α transgenic mice by inducing hypertrophy and inhibiting apoptosis
Open Access
- 1 January 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 20 (1) , 41-49
- https://doi.org/10.1093/carcin/20.1.41
Abstract
Phenobarbital (PB) is a non-genotoxic liver tumor promoter used extensively in initiation–promotion protocols. To determine the mode of PB action, double transgenic mice overexpressing both the c-myc and transforming growth factor (TGF)-α genes were treated with PB in the food for 10 weeks, from 3 weeks of age. After 3–4 weeks on PB a peak in liver mass was noted, which subsequently leveled off at a value ~30% above untreated animals. The mitotic index in mice given PB peaked at 1 week of treatment and was significantly elevated compared with untreated animals. No significant difference between treated and untreated animals was seen thereafter, although a trend of PB-associated mitotic suppression was noticeable. The apoptotic index also showed a trend of suppression compared with untreated animals, significant after prolonged PB administration. Dysplastic hepatocytes were more prominent in PB-treated mice than untreated animals, particularly pericentrally. Removal of PB from the diet at 4 weeks of treatment led to a dramatic increase in apoptosis. This accompanied a drop in the liver mass to the level of untreated controls by 10 days. Throughout the study, PB-treated animals showed markedly lower levels of TGF-β1 ligand, coincident with an elevated level of the anti-apoptotic protein Bcl-2. On withdrawal of PB, the levels of all these proteins rapidly changed to mirror those seen in untreated mice. In all treatment groups, no change in the levels of epidermal growth factor receptor, TGF-β receptors I and II or Bcl-xS/L were seen. We conclude from our data that PB stimulates liver growth in double transgenic c-myc/TGF-α mice by induction of liver hypertrophy and inhibition of apoptosis, brought about by both a decrease in signaling through the TGF-β pathway and an increase in Bcl-2. The data support the hypothesis that PB promotes neoplastic development through a reduction in the incidence of cell death.Keywords
This publication has 38 references indexed in Scilit:
- Responsiveness of hepatocytes from dichloroacetic acid or phenobarbital treated mice to growth factors in primary cultureCancer Letters, 1996
- Induction of cytochrome P-4502B1-related mouse cytochrome P-450 and regulation of its expression by epidermal growth factor/transforming growth factor α in primary hepatocyte cultureBiochemical Pharmacology, 1995
- Modulation of phenobarbitone-induced loss of gap junctional intercellular communication in hepatocyte coupletsCarcinogenesis: Integrative Cancer Research, 1994
- Long-term treatment with hepatic tumor promoters inhibits mitogenic responses of hepatocytes to acidic fibroblast growth factor and hepatocyte growth factorCancer Letters, 1991
- Liver tumor promotion: Effect of phenobarbital on EGF and protein kinase C signal transduction and transforming growth factor-?1 expressionDigestive Diseases and Sciences, 1991
- Responsiveness of hepatocytes to epidermal growth factor, transforming growth factor-beta and norepinephrine during treatment with xenobiotic hepatic tumor promotersCancer Letters, 1991
- The effect of phenobarbital on the metabolism and excretion of thyroxine in ratsToxicology and Applied Pharmacology, 1989
- Phenobarbital reduces EGF receptors and the ability of physiological concentrations of calcium to suppress hepatocyte proliferationCarcinogenesis: Integrative Cancer Research, 1988
- Is phenobarbital carcinogenic? A follow-up of 8078 epilepticsEcotoxicology and Environmental Safety, 1978
- Enhancement of Spontaneous Hepatic Tumorigenesis in C3H Mice by Dietary Phenobarbital2JNCI Journal of the National Cancer Institute, 1973